Gut microbiome during ozone treatment for chemotherapy-related nerve symptoms
About this title
Read the official source — NCT06799351Understand this study
Who could participate?
Listed age limits: from 18 years.
What will I do during this study?
This add-on observational study follows people already receiving chemotherapy and taking part in the OzoParQT trial. Depending on their assigned group, they receive usual care plus 40 rectal ozone or oxygen sessions over 16 weeks. The add-on study examines stool microbiome profiles alongside nerve symptoms and other outcomes.
- Listed locations
- Las PalmasSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 42
- Sponsor
- Bernardino Clavo, MD, PhD
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Spain
- Age range
- Over 18 Years
- Official registry ID
- NCT06799351
- Official title
Show the full official title
Evaluation of the Gut Microbiome Profiles in Patients With Chemotherapy-induced Peripheral Neuropathy Treated in the Randomized Clinical Trial With Ozone OzoParQT (NCT06706544).
Recruitment & locations
Las Palmas
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Bernardino Clavo, MD, PhD.
Does this study involve medication?
Yes. The study involves medication, including Oxygen (placebo).
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as recruiting.
